Su YW, Qiu YZ, Wang YH, Xu Y, et al. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
PMID: 38461050